20-F: Compugen Inks Exclusive Licensing Deal with Gilead for Novel Immunotherapy Program, COM503

Compugen grants Gilead exclusive rights to its preclinical antibody program targeting IL-18 binding protein, including COM503, for a potential $848 million deal.

Summary

• Compugen Ltd. has entered into an exclusive licensing agreement with Gilead Sciences, Inc. for its preclinical antibody program targeting IL-18 binding protein, including the drug candidate COM503.
• Under the agreement, Gilead gains exclusive rights to research, develop, manufacture, and commercialize products from the program.
• Compugen will receive a $60 million upfront payment and is eligible for a $30 million milestone payment upon IND clearance for COM503.
• The agreement includes potential development, regulatory, and commercial milestone payments totaling up to $758 million, plus tiered royalties on worldwide net sales.
• Compugen will conduct the Phase 1 clinical trial for COM503, with Gilead providing an anti-PD-1/PD-L1 antibody for the trial.
• Gilead will then assume responsibility for further development and commercialization.
• The total potential value of the deal is $848 million, plus royalties.

Sentiment

Score: 8

Explanation: The document is positive due to the significant licensing agreement with Gilead, which provides substantial upfront funding and potential future revenue. The deal validates Compugen's technology and strengthens its financial position.

Positives

• The licensing agreement provides Compugen with significant upfront funding and potential future revenue through milestone payments and royalties.
• Gilead's involvement validates Compugen's computational discovery capabilities and preclinical development efforts.
• The partnership allows Compugen to advance COM503 through Phase 1 clinical trials while leveraging Gilead's expertise and resources for later-stage development and commercialization.
• The agreement strengthens Compugen's financial position and extends its cash runway.

Negatives

• Compugen is giving up exclusive control over the future development and commercialization of COM503.
• The receipt of milestone payments and royalties is contingent upon the successful development and commercialization of COM503 by Gilead, which is subject to various risks and uncertainties.
• The agreement restricts Compugen from independently pursuing research and development of other products targeting IL-18.

Risks

• The success of COM503 is dependent on Gilead's ability to successfully develop and commercialize the drug, which is subject to clinical, regulatory, and market risks.
• Compugen may not receive all potential milestone payments or royalties if COM503 fails to achieve certain development or commercial targets.
• The agreement restricts Compugen from independently pursuing research and development of other products targeting IL-18.
• Gilead may terminate the agreement under certain circumstances, which would impact Compugen's future revenue stream.

Future Outlook

Compugen and Gilead will collaborate on the Phase 1 clinical trial for COM503, after which Gilead will assume responsibility for further development and commercialization. Compugen is eligible to receive milestone payments and royalties based on the success of COM503.

Management Comments

• Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences: 'We are very pleased to add COM503 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer.'
• Anat Cohen-Dayag, Ph.D., President, and CEO at Compugen: 'We are delighted to enter into this collaboration with Gilead and believe that Gileads confidence in our differentiated approach to harness cytokine biology for cancer therapeutics speaks to the quality of our computational discovery capabilities as well as our ability to translate our novel discoveries into investigational drugs in the clinic and we look forward to working together to bring new treatment options to patients.'

Industry Context

This agreement reflects the ongoing interest in immuno-oncology and the potential of novel targets like IL-18 binding protein to improve cancer treatment outcomes. It also highlights the increasing trend of pharmaceutical companies collaborating with smaller biotech firms to access innovative technologies and drug candidates.

Comparison to Industry Standards

• Deals in the immuno-oncology space vary widely, but upfront payments and potential milestone payments are often significant, reflecting the high-risk, high-reward nature of drug development.
• Comparable deals include those between larger pharmaceutical companies and smaller biotech firms with promising preclinical or early-stage clinical assets.
• For example, similar deals for preclinical assets in oncology have included upfront payments ranging from tens of millions to hundreds of millions of dollars, with potential milestone payments reaching billions.
• The specific terms of each deal depend on the stage of development, the target, the competitive landscape, and the perceived value of the asset.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to the licensing agreement and future milestone payments and royalties.
• Employees: Job security and potential for career advancement due to the company's strengthened financial position and pipeline development.
• Patients: Potential for new and improved cancer treatment options through the development of COM503.
• Gilead: Access to a promising preclinical asset and potential for new revenue streams in the oncology market.

Next Steps

• Compugen will continue preclinical development and conduct the Phase 1 clinical trial for COM503.
• Gilead will assume responsibility for further development and commercialization after Phase 1.
• The companies will work together to achieve IND clearance for COM503.
• The companies will work together to achieve development, regulatory, and commercial milestones.

Key Dates

Keywords

COM503, Gilead, licensing agreement, IL-18 binding protein, immunotherapy, Compugen, antibody, oncology